科伦药业
(002422)
| 流通市值：382.80亿 | | | 总市值：469.11亿 |
| 流通股本：13.07亿 | | | 总股本：16.02亿 |
| 报告期 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 15,743,097,216 | 10,733,926,609 | 5,601,800,088 | 18,912,653,463 |
| 营业收入 | 15,743,097,216 | 10,733,926,609 | 5,601,800,088 | 18,912,653,463 |
| 二、营业总成本 | 13,469,903,968 | 9,088,100,822 | 4,622,367,333 | 17,094,021,282 |
| 营业成本 | 7,409,716,721 | 5,015,003,406 | 2,526,606,529 | 8,959,199,166 |
| 税金及附加 | 232,751,027 | 154,222,843 | 63,541,288 | 251,024,095 |
| 销售费用 | 3,249,237,667 | 2,179,052,030 | 1,159,695,620 | 4,685,947,670 |
| 管理费用 | 706,770,112 | 498,169,144 | 285,361,489 | 924,584,823 |
| 研发费用 | 1,665,659,341 | 1,075,856,695 | 491,663,537 | 1,795,088,422 |
| 财务费用 | 205,769,100 | 165,796,704 | 95,498,870 | 478,177,106 |
| 其中:利息费用 | 291,195,563 | 229,860,423 | 124,902,212 | 473,709,607 |
| 其中:利息收入 | 75,907,728 | 48,204,106 | 16,735,095 | 44,219,859 |
| 加:公允价值变动收益 | -87,183 | 3,264,144 | 1,476,680 | 9,861,194 |
| 加:投资收益 | 266,981,025 | 170,496,770 | 88,350,065 | 234,426,987 |
| 资产处置收益 | 1,906,464 | 1,637,311 | -1,165,569 | 5,397,599 |
| 资产减值损失(新) | -46,598,036 | -46,598,036 | -14,721,824 | -44,030,990 |
| 信用减值损失(新) | -77,342,737 | -37,077,927 | -9,094,001 | -62,451,839 |
| 其他收益 | 179,426,495 | 140,017,547 | 78,808,008 | 237,024,581 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 2,597,479,276 | 1,877,565,596 | 1,123,086,114 | 2,198,859,713 |
| 加:营业外收入 | 4,515,413 | 1,939,789 | 557,530 | 7,025,103 |
| 减:营业外支出 | 56,199,401 | 26,320,047 | 12,358,310 | 134,420,979 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 2,545,795,288 | 1,853,185,338 | 1,111,285,334 | 2,071,463,837 |
| 减:所得税费用 | 402,765,455 | 275,539,483 | 155,344,257 | 364,001,973 |
| 六、净利润 | 2,143,029,833 | 1,577,645,855 | 955,941,077 | 1,707,461,864 |
| 持续经营净利润 | 2,143,029,833 | 1,577,645,855 | 955,941,077 | 1,707,461,864 |
| 归属于母公司股东的净利润 | 1,963,327,343 | 1,402,202,255 | 810,322,186 | 1,708,702,516 |
| 少数股东损益 | 179,702,490 | 175,443,600 | 145,618,891 | -1,240,652 |
| (一)基本每股收益 | 1.35 | 0.97 | 0.56 | 1.22 |
| (二)稀释每股收益 | 1.27 | 0.91 | 0.52 | 1.15 |
| 八、其他综合收益 | 73,410,076 | 87,050,521 | -48,712,389 | 241,242,829 |
| 归属于母公司股东的其他综合收益 | 70,759,783 | 84,698,584 | -48,204,271 | 236,679,190 |
| 九、综合收益总额 | 2,216,439,909 | 1,664,696,376 | 907,228,688 | 1,948,704,693 |
| 归属于母公司股东的综合收益总额 | 2,034,087,126 | 1,486,900,839 | 762,117,915 | 1,945,381,706 |
| 归属于少数股东的综合收益总额 | 182,352,783 | 177,795,537 | 145,110,773 | 3,322,987 |
| 公告日期 | 2023-10-31 | 2023-08-30 | 2023-04-26 | 2023-04-14 |
| 审计意见(境内) | | | | 标准无保留意见 |